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 Abstract 
Metastases from salivary gland carcinomas to the cervi-
cal lymph nodes are relatively uncommon. However, 
their impact on prognosis is significant and, thus, it is
important to manage them appropriately. Treatment of 
clinically evident metastases consists primarily of sur-
gery, frequently followed by radiation. Management of 
the N0 neck, on the other hand, remains controversial. 
While there seems to be agreement regarding the tumor 
and patient factors that make it more likely for a patient 
to harbor subclinical metastases in the lymph nodes, 
some clinicians prefer to treat those patients with sur-
gery, i.e. a neck dissection, and others prefer to use elec-
tive radiation. These different approaches and their ratio-
nale will be discussed in detail.  © 2016 S. Karger AG, Basel 
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 Introduction 
 Metastasis to the cervical lymph nodes is relative-
ly uncommon in carcinomas of the salivary 
glands; around 15% of parotid cancers and 8–10% 
of submandibular and sublingual tumors present 
with clinical evidence of nodal metastasis  [1] . Al-
though rare, tumor involvement of the lymph 
nodes has a major influence on prognosis. A sig-
nificant difference has been noted between the 
survival rates of patients with cancer of the pa-
rotid with and without histologically proven 
lymph node metastasis of 70 versus 10%, respec-
tively. The corresponding rates for patients with 
submandibular gland cancer are 41 and 9%, re-
spectively  [2, 3] . Similar differences in the 5- and 
10-year overall survival rates have been reported 
more recently  [4, 5] . Therefore, appropriate man-
agement of the regional lymph nodes is impor-
tant in the treatment of patients with carcinoma 
of the major salivary glands. 
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 The Clinically Positive Neck 
 Treatment of salivary gland cancer with clinically 
or radiologically obvious lymph node metastases 
consists of neck dissection (ND), followed in 
most cases by postoperative radiation. The type 
of ND is determined by the extent of nodal dis-
ease, with the purpose of the operation being the 
removal of all gross tumor present. For patients 
with parotid carcinomas who have a single in-
volved node in level II, dissection of levels II-IV 
may be appropriate, while dissection of levels I-V 
may be necessary in patients with multiple pal-
pable nodes in different levels of the neck. In pa-
tients with submandibular gland carcinoma who 
have undergone therapeutic ND, lymph node 
metastases have been found in all neck levels. 
Level I is the most frequently involved; however, 
high rates of lymph node metastases in levels IV 
(40%) and V (25%) have been reported  [6] . Com-
plete resection of the involved nodes can often be 
accomplished with preservation of the spinal ac-
cessory nerve, the sternocleidomastoid muscle, 
or the internal jugular vein. 
 The addition of postoperative radiation ap-
pears to be of value for patients with salivary 
gland cancer who have cervical lymph node me-
tastases. While there are no prospective or ran-
domized studies to support this use of postopera-
tive radiation, the results of several retrospective 
reports have indicated that it improves local-re-
gional control and survival  [7–9] . Armstrong et 
al.  [10] performed matched-pair analysis of pa-
tients treated for salivary cancer with nodal me-
tastasis, with one cohort of patients receiving 
surgery alone and the other cohort receiving 
postoperative radiation. Each cohort included 46 
patients matched according to age and tumor 
type, grade and stage. Treatment of stage III and 
IV cancers with postoperative radiotherapy re-
sulted in better loco-regional control and surviv-
al compared with treatment with surgery alone. 
However, patients with low-grade or early-stage 
(I/II) disease did not appear to benefit from the 
addition of radiation. Terhaard  [11] analyzed the 
roles of primary and postoperative radiotherapy 
in 538 patients treated for salivary gland cancer in 
the Netherlands. The tumor was located in the 
parotid gland in 59% of the patients, the subman-
dibular gland in 14%, the oral cavity in 23%, and 
elsewhere in 5%. In 386 of 498 patients, surgery 
was combined with radiotherapy, with a median 
dose of 62 Gy. Postoperative radiotherapy signif-
icantly improved regional control in the clinically 
positive (N+) neck (86 vs. 62% for surgery alone). 
A more recent study of 50 patients with parotid 
gland cancer treated in the United Kingdom 
demonstrated excellent local control (96%) with 
surgery and postoperative radiotherapy  [12] .
 The beneficial effect of postoperative radiation 
has also been suggested in studies of patients with 
submandibular gland and minor salivary gland 
cancers  [13–16] . It is unclear, however, whether 
radiation should be prescribed to every patient 
with histologically positive nodes  [17] or only to 
those with multiple positive nodes or extranodal 
tumor extension  [18] .
 Although the results of recent studies of the 
use of combined therapy for treatment of the N+ 
neck in salivary gland cancers look promising, 
they still leave a lot to be desired  [10, 17] . In anal-
ysis of malignant tumors of major salivary gland 
origin, Armstrong et al. found a 5-year local-re-
gional control rate of 69% for a group of 23 pa-
tients with lymph node metastases who received 
radiation to the neck and of 40% for a group of 16 
patients treated with surgery alone (p = 0.05). 
The corresponding survival rates were 49 and 
19%, respectively (p = 0.015). More recently, a 
single institution report has suggested that com-
bining radiation with platinum-based chemo-
therapy may improve long-term survival among 
patients with locally advanced salivary gland car-
cinoma  [19] . Thus, this treatment approach war-
rants investigation in patients with salivary gland 
carcinoma and clinically obvious lymph node 
metastases.
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 The Clinically Negative Neck 
 There is no general agreement to date about the 
management of the clinically negative (N0) neck 
in patients with cancer of the major salivary 
glands. The different management strategies that 
have been recommended over the years are out-
lined in  table 1 . 
 In a paper published in 1967 reporting a study 
that included 111 patients with malignant tu-
mors of the parotid gland treated at MD Ander-
son Cancer Center, Bardwil  [20] stated that elec-
tive ND had not been performed during the last 
5 years of the study because he had found occult 
metastases in only 1 of 34 (2.9%) patients who 
had undergone this operation. Interestingly, 
however, he advocated ‘careful dissection of the 
first echelon of lymph nodes for all lesions,’ 
claiming that this adds little or no morbidity to 
the operation and if the tumor proves to be ma-
lignant, the procedure is generally adequate. For 
the next 2 decades, the surgeons at MD Anderson 
subscribed to this approach to the N0 neck in pa-
tients with salivary gland tumors  [18, 21] . Then, 
in 1993, Frankenthaler et al.  [22] reported the re-
sults of multivariate analysis of 11 clinical and 
histopathologic variables in patients who had un-
dergone elective node dissection for cancer of the 
parotid gland. The factors that were correlated 
with the presence of occult cervical lymph node 
metastases were facial paralysis, an older age (>54 
years), a high tumor grade, perilymphatic inva-
sion, and extraparotid tumor extension. Inter-
estingly, with the exception of older age, these 
factors were also associated with increased local 
recurrence and thus dictate the need for post-
operative radiation, regardless of the presence or 
absence of occult metastases in the regional 
lymph nodes  [23] . Another interesting finding of 
this study was that occult metastases were discov-
ered by elective dissection of the lymph nodes in 
only 3% of the patients with low-grade tumors. 
Although staging ND may be helpful for deter-
mining the need for postoperative radiation in 
this group of patients, the operation would be 
unnecessary in 97% of the cases. In 1980, Johns 
[24] carried out a review of the literature and of 
the experience of the University of Virginia with 
the treatment of parotid tumors. He advocated 
treating the neck on the basis of the stage and 
histology of the primary tumor and felt that ND 
was indicated in patients with tumors of stages 
T3 and T4; for T1 through T2 tumors of high-
grade histology, he advocated dissection of the 
first echelon of lymph nodes  [24] . In 1989, Spiro 
et al. [25] published a review of 44 years of expe-
rience at the Memorial Sloan-Kettering Cancer 
Center. This group stated that elective ND may 
be beneficial in patients with anaplastic or squa-
mous carcinoma because 58% or more of them 
will develop cervical metastases. Staging supra-
omohyoid ND was thought to be appropriate for 
patients with other types of high-grade tumors 
 [25] . A few years later, similar recommendations 
were made by Califano et al.  [26] from the Uni-
versity of Naples. A later study from Memorial 
Sloan-Kettering suggested that in patients with 
small, low-grade tumors that are adequately ex-
cised, elective treatment of the neck is not neces-
sary  [23] . On the other hand, this treatment is 
warranted in patients whose tumors are larger 
than 4 cm or are high grade and in whom the risk 
of occult lymph node metastases is high  [24] . In 
yet a different review of the same patient popula-
tion, Armstrong et al.  [1] advanced the notion 
that in the high-risk group, the N0 neck could be 
treated with either elective ND (incorporating at 
least levels I, II, and III) or ‘elective postoperative 
neck irradiation.’ They suggested that it may be 
reasonable to treat the neck electively with radia-
tion for patients for whom postoperative radia-
tion therapy is indicated according to the char-
acteristics of the primary tumor. Their recom-
mendation is based on the extensive experience 
reported, which indicates that either radiation 
therapy to the neck or ND can control clinically 
occult cervical metastases in epidermoid carci-
noma of the head and neck.
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 As shown in  table 1 , the debate continues to 
date, with some clinical studies suggesting that 
the appropriate treatment of the N0 neck is either 
ND or postoperative neck irradiation in select 
cases  [27] and others suggesting that elective ND 
should be performed in all cases  [28] .
 An important consideration in selective ap-
proaches to management of the N0 neck is the 
definition of a ‘high-risk’ tumor with regard to 
the risk of occult metastases in the lymph nodes. 
Today, it is generally accepted that the tumor 
histology, T stage and tumor grade are the most 
consistent predictors of the presence of nodal 
metastases. The risk of metastases is approxi-
mately 50% or higher when the tumor histology 
is undifferentiated carcinoma, adenocarcinoma, 
salivary duct carcinoma or squamous cell carci-
noma. The risk is similarly high for high-grade 
mucoepidermoid carcinoma, unlike low-grade 
mucoepidermoid carcinoma and acinic cell car-
Table 1.  The N0 neck in salivary gland cancer: management strategies over time
Bardwill [20], 1967 No elective radical neck dissection
Dissection of first echelon nodes for all tumors
Johns [24], 1980 T1–T2: No neck dissection
T3–T4: Neck dissection and radiation
Byers [21], 1982 Dissection of first echelon nodes in all tumors
Spiro et al. [25], 1989 Elective neck dissection for anaplastic or squamous carcinoma
Staging supraomohyoid neck dissection for other high-grade tumors
Armstrong et al. [1], 1992 Elective neck dissection or elective postoperative neck irradiation for ‘high-risk’ 
tumors
Califano et al. [26], 1993 Neck dissection in cases of mucoepidermoid, anaplastic, and squamous cell 
carcinomas
Ball et al. [41], 1995 Neck dissection: high-grade tumors with positive jugulodigastric node biopsy 
(intraoperative frozen section)
Frankenthaler et al. [22], 1993 No elective neck dissection
Elective postoperative neck irradiation for high-risk tumors
Kelley and Spiro [17], 1996 Elective treatment of the neck for tumors larger than 4 cm or high-grade tumors
Medina [33], 1998 Intraoperative assessment of level II nodes
If suspicious and frozen section examination reveals metastases: ND
Otherwise, elective postoperative neck irradiation if the primary tumor exhibits 
high-risk clinical-pathological characteristics
Wang et al. [42], 2012 Comprehensive ND and postoperative radiation: high-risk tumors with adverse 
features
Upper ND; postoperative radiation: moderate-risk tumors, depending on adverse 
factors and pN status
Observation: low-risk tumors without adverse features
Herman et al. [27], 2013 T3–T4: Elective neck irradiation if postoperative radiation is indicated preoperatively 
(based on primary tumor characteristics)
Norbis et al. [28], 2014 Elective neck dissection for all patients
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cinoma, for which the risk is 2–4%  [1, 22, 29] . 
The reported prevalence of lymph node metas-
tases also varies according to the disease stage, 
ranging from 16 to 33% for T3 tumors and from 
24 to 50% for T4 tumors  [1, 8, 26] . Beppu et al. 
 [30] found that the incidence of lymph node me-
tastases in patients with submandibular gland 
carcinoma ranged from 0% in T1 tumors to 
33.3% in T2, 57.1% in T3 and 100% in T4 tu-
mors. Other factors that have been reported to 
be correlated with the presence of lymph node 
metastases in salivary gland tumors are listed in 
 table 2 .
 It is interesting to note that the currently ac-
cepted indications for prescribing postoperative 
radiation in patients with carcinoma of the sali-
vary gland also include high risk and high-grade 
histology, stages T3 and T4, extraparotid exten-
sion, perineural invasion, a deep lobe location, 
close or positive margins and the presence of 
lymph node metastases  [31–33] .
 Consequently, Medina  [33] reasoned, along 
the lines suggested by Armstrong et al.  [1] , that 
since the characteristics of salivary gland carci-
nomas that dictate the need for elective treat-
ment of the regional lymph nodes are, in es-
sence, the same characteristics that dictate the 
need for postoperative radiation to the primary 
lesion, then it seems reasonable to treat the neck 
with elective irradiation in patients whose tu-
mors exhibit these characteristics after adequate 
surgery of the primary tumor. Although this ap-
proach to the N0 neck seems logical, it has been 
criticized because it has not been tested prospec-
tively, and it is assumed that elective neck irra-
diation is efficacious in the control of occult 
lymph node metastases from salivary gland car-
cinomas. Interestingly, two recent studies, albeit 
retrospective, have lent support to this approach. 
Chen et al.  [31] studied 251 patients with carci-
noma of the salivary glands and a clinically N0 
neck who were treated with surgery and postop-
erative radiation therapy and who had not un-
dergone previous ND. Postoperative elective 
neck irradiation reduced the 10-year nodal fail-
ure rate from 26 to 0% (p = 0.0001). The highest 
crude rates of nodal relapse among patients 
treated without elective neck irradiation were 
observed in those with squamous cell carcinoma 
(67%), undifferentiated carcinoma (50%), ade-
nocarcinoma (34%), and mucoepidermoid car-
cinoma (29%). There were no nodal failures ob-
served among patients with adenoid cystic or 
acinic cell carcinoma. These authors concluded 
that elective postoperative irradiation effectively 
prevents nodal relapses and should be used for 
select patients at high risk of regional failure. 
The second study was conducted by Herman et 
al. [27] to determine whether patients with high-
grade salivary gland carcinoma and a clinically 
node-negative neck benefit from elective ND 
performed prior to postoperative radiotherapy. 
They studied 59 previously untreated patients 
with high-grade salivary gland carcinoma and 
an N0 neck who were treated with curative in-
tent using elective ND (n = 41) or elective neck 
irradiation (n = 18). These patients underwent 
resection of the primary tumor followed by post-
operative radiation. During a median follow-up 
period of 5.2 years (range, 0.3–34 years), there 
were 4 recurrences (10%) in the ND group and 0 
in the neck irradiation group. They concluded 
that patients with high-grade salivary gland car-
cinoma and a clinically N0 neck who have un-
dergone surgery and postoperative radiation are 
not likely to benefit from ND  [27] .
Table 2.  Variables correlated with the presence of lymph 
node metastases in cancers of the major salivary glands
1 High-grade tumors
2 T3 (?) and T4 tumors
3 Facial paralysis
4 Older age (>54 years [22], >70 years [43])
5 Extraparotid extension [42]
6 Lymphovascular invasion
7 Facial paralysis and perineural invasion [22, 33]
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 Sentinel Node Biopsy in Primary Parotid 
Cancer 
 The incidence of occult metastasis in elective 
neck dissection (END) specimens has been re-
ported to be between 20 and 37%  [34, 35] . Thus, 
the performing of END for all cN0 parotid can-
cers implies that more than half of patients are 
over-treated. Sentinel node biopsy (SNB) is a 
90%
a
b
 Fig. 1. a Distribution of occult lymph node metastases in 
parotid cancers. b Intraoperative photograph of paroti-
dectomy and selective neck dissection of levels II and III. 
100%
a
b
 Fig. 2. a Distribution of occult lymph node metastases in 
carcinomas of the submandibular gland in levels II and III. 
b Intraoperative photograph of selective neck dissection 
of levels I (submandibular triangle), II and III. 
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technique used to select patients with occult me-
tastases who would benefit from ND. The senti-
nel lymph node is the first node (in many cases, 
there are several sentinel nodes) to receive drain-
age from the primary tumor site. It is therefore 
the initial possible recipient of metastatic tumor 
cells and may be predictive of the histopatholog-
ic status of the remaining lymphatic neck area 
 [36] . The SNB concept was introduced for nodal 
evaluation of head and neck squamous cell car-
cinomas localized to the oral cavity and oro-
pharynx. It was determined to be a valid pro-
cedure for avoiding END and its potential mor-
bidity  [36] . As for primary parotid carcinoma, 
experience with SNB is very limited, although 
one of the first such reported experiences in-
volved patients treated for parotid carcinoma 
 [37] . Gould et al. [37] observed the so-called an-
gular node in 28 parotid carcinomas; they based 
the decision on whether to perform ND on the 
results of frozen section analysis of this node. 
Thereafter, several authors suggested ‘dissection 
of the first echelon of lymph nodes’  [20, 24] or 
‘jugulodigastric node biopsy’ with intraopera-
tive frozen section analysis  [33] . 
 Approximately 80% of parotid carcinomas 
arise in the superficial lobe. In many of these cas-
es, the first echelon is represented by the intra-
parotid lymph nodes. The mean numbers of in-
traparotid lymph nodes that have been reported 
are 7 (range, 3–19) in the superficial lobe and 2 
(range, 0–9) in the deep lobe  [38] . Furthermore, a 
statistically significant correlation (p = 0.005) has 
been observed between the presence of intrapa-
rotid metastatic nodes and neck node metastases 
 [39] . Unfortunately, the lymphoscintigraphic 
identification of intraparotid nod metastases is 
challenging in many cases. The nodes can be eas-
ily missed due to close proximity to the primary 
tumor and injection site.
 In 2006, Starek et al.  [40] reported a study of 6 
patients who underwent SNB; in all cases, selec-
tive neck dissection level II–V was performed. 
Two patients had true-positive results for the sen-
tinel node, and there was one false-negative result 
that was interpreted as ‘distortion of the lymphat-
ic outflow resulting from intraparotid localiza-
tion of lymphatic metastases’.
 There are several documented reasons why 
there is no experience with performing SNB for 
parotid carcinoma: the lymphoscintigraphic 
identification of intraparotid lymph nodes may 
be difficult in many cases; intraparotid lymph 
nodes can be examined by frozen section analysis 
of a parotidectomy specimen; and lymphadenec-
tomy of suspected nodes in level II for frozen sec-
tions or even END of level II or level III can eas-
ily be incorporated into the surgical approach 
with minimal morbidity and only a slight increase 
in operative time.
 Conclusion 
 Regardless of whether a clinician chooses to treat 
an N0 neck with elective ND or elective postop-
erative radiation, only the ipsilateral side of the 
neck should be treated. The occurrence of contra-
lateral lymph node metastases in tumors of the 
major salivary gland is negligible  [17] . 
 If a clinician elects to treat an N0 neck with 
ND, the type of ND should be tailored according 
to the distribution of occult metastases in patients 
with salivary gland carcinoma. The distribution 
of lymph node metastases in parotid carcinoma 
has been studied by Armstrong et al.  [1] . Beppu et 
al.  [30] noted that pathological neck lymph node 
metastases were found in levels II and III only in 
27 patients with submandibular gland carcinoma 
staged as N0. Others have reported similar find-
ings  [6] ( fig. 1,  2 ).
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